LMP Capital and Income Fund Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCD research report →
Price Chart
About the company
The LMP Capital and Income Fund Inc. operates as a closed-end balanced mutual fund, primarily overseen by Legg Mason Partners Fund Advisor, LLC. Additional management responsibilities are shared with Clearbridge Investments, LLC, Western Asset Management Company Limited, and Western Asset Management Company.
- CEO
- Kenneth Donald Fuller
- IPO
- 2004
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on SCD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.93B
- P/E
- 5.24
- PEG
- 0.02
- P/S
- 424.48
- P/B
- 0.85
- EV/EBITDA
- 73.63
- Div Yield
- 9.78%
- Gross Margin
- 97.54%
- Op Margin
- 306.39%
- Net Margin
- 553.49%
- ROE
- 16.62%
- ROIC
- 7.08%
Latest fiscal year · YoY change
- Revenue
- $54.77M-37.7%
- Gross Profit
- $54.53M-37.9%
- Op Income
- $2.89M
- Net Income
- $-820,206-100.9%
- EPS
- $-0.04-100.7%
- OCF Growth
- -64.4%
- FCF Growth
- -64.4%
- 52W High
- $16.18
- 52W Low
- $13.79
- 50D MA
- $15.36
- 200D MA
- $15.36
- Beta
- 0.97
- RSI (14)
- 32
- Avg Volume
- 84.30K
No earnings-call transcripts are available for SCD yet.
- Free Float
- 97.3%
- Shares Outstanding
- 335.03M
- Float Shares
- 326.03M
of shares held by institutions
53 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Sit Investment Associates Inc | 2.64M | ▼ 143.84K |
| Raymond James Financial Inc | 1.25M | ▼ 515.71K |
| Z3 Capital Partners, LLC | 425.70K | ▲ 5.37K |
| Morgan Stanley | 411.79K | ▼ 21.16K |
| Penserra Capital Management LLC | 400.67K | ▲ 15.25K |
| Shaker Financial Services, LLC | 333.41K | ▲ 333.41K |
| Wells Fargo & Company/Mn | 327.37K | ▲ 26.70K |
| Allspring Global Investments Holdings, LLC | 234.39K | ▲ 167.69K |
| Steward Partners Investment Advisory, LLC | 169.84K | ▼ 80.92K |
| Wealth Enhancement Advisory Services, LLC | 169.54K | ▲ 23.96K |
| Advisors Asset Management, Inc. | 148.99K | ▲ 24.32K |
| Wolverine Asset Management LLC | 142.75K | ▲ 59.66K |
Held by 2 ETFs
Biggest fund positions in SCD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 1, 26 | Mossman Brett Michael | other | 0 |
| Sep 1, 26 | Doyle Ann Elizabeth | other | 0 |
| Dec 1, 25 | Stout Kim | other | 0 |
| Jan 1, 26 | Haller John | other | 0 |
| Jan 1, 26 | Eakes Brian | other | 0 |
| Apr 29, 25 | Masom Jeffrey | other | 0 |
| Jul 14, 25 | Mason Peter Daniel Charles | buy | 2,580 |
| May 27, 25 | GRILLO ANTHONY | buy | 700 |
| Apr 15, 25 | Oh Seok Selene | other | 0 |
| Dec 3, 24 | Gahan Thomas | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SCD coverage
Recent articles, reports, and earnings notes.
No research on SCD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SCD report →FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition
globenewswire.com · Oct 7
Roche launches newborn screening test for three severe genetic conditions
gurufocus.com · Sep 30
SCD: High Midstream/Low Bond Exposure Is A Good Combination
seekingalpha.com · Sep 2
10 Best CEFs This Month: Average Yield Of Near 10% (August 2026)
seekingalpha.com · Aug 29
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
prnewswire.com · Jul 28
10 Best CEFs This Month: Average Yield Of Near 10% (July 2026)
seekingalpha.com · Jul 25
LMP Capital and Income Fund (NYSE:SCD) Stock Price Passes Below 200 Day Moving Average – Time to Sell?
defenseworld.net · Jul 22
Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
prnewswire.com · Jul 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.